Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-014583
Filing Date
2025-02-05
Accepted
2025-02-05 16:40:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 29526
  Complete submission text file 0000950170-25-014583.txt   31210
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 800E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 800E CAMBRIDGE MA 02142 617-868-1888
Flagship V VentureLabs Rx Fund, L.P. (Filed by) CIK: 0001724939 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A

Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Subject) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92749 | Film No.: 25593930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)